kabutan

AnGes, Inc.(4563) Summary

4563
TSE Growth
AnGes, Inc.
57
JPY
+1
(+1.79%)
Mar 13, 3:30 pm JST
0.35
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
56.7
Mar 14, 12:44 am JST
Summary Chart Historical News Financial Result
PER
PBR
7.56
Yield
ー%
Margin Trading Ratio
8.26
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
56 JPY 0.35 USD
Previous Close Mar 12
56 JPY 0.35 USD
High Mar 13, 9:00 am
57 JPY 0.35 USD
Low Mar 13, 9:00 am
56 JPY 0.35 USD
Volume
868,600
Trading Value
0.05B JPY 0.31M USD
VWAP
56.27 JPY 0.35 USD
Minimum Trading Value
5,700 JPY 35 USD
Market Cap
0.02T JPY 0.14B USD
Number of Trades
178
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
621
1-Year High Aug 12, 2025
5,987
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,357,600 25,631,600 18.88
Feb 27, 2026 1,334,700 25,948,300 19.44
Feb 20, 2026 1,350,500 25,419,700 18.82
Feb 13, 2026 1,348,500 28,995,400 21.50
Feb 6, 2026 1,327,600 29,502,600 22.22
Company Profile
AnGes, Inc. is a biotech venture founded by an Osaka University professor, developing gene therapies and other pharmaceuticals. The company also sells treatments for intractable diseases.
Sector
Pharmaceuticals
AnGes, Inc. is a biotech venture originating from Osaka University Medical School, focusing on the development and sale of pharmaceuticals, particularly gene therapies. The company also provides contract testing services, primarily for rare genetic disease screening. Its subsidiary, EmendoBio Inc., possesses advanced genome editing technologies and is engaged in research and development of new treatments using genome editing products. In 2019, AnGes obtained conditional and time-limited manufacturing and marketing approval for "Collategene," the world's first plasmid DNA-based gene therapy product. The company has entered into an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for the Japanese market, and has begun sales, recording product sales revenue.